Featured projects

  • A European Cancer Image Platform Linked to Biological and Health

    Principal investigator: Aleix Prat Aparicio.
    Funder: Horizon 2020 Framework Programme .
    Code: 952103 — EuCanImage.
    Duration: 01/10/2020 - 30/09/2024
  • Identification of mechanisms of response to CDK4/6 inhibition in hormone receptor-positive breast cancer

    Principal investigator: Aleix Prat Aparicio.
    Funder: IRB (Participante); Fundació La Marató de TV3 ; IDIBELL (Participante); IDIBAPS (Sede).
    Code: 201935-30-31-32.
    Duration: 30/07/2020 - 29/07/2023
    Summary:

    Hormone receptorpos

  • RESCUER. Resistance Under Combinatorial Treatment in ER+ and ER- Breast Cancer.

    Principal investigator: Aleix Prat Aparicio.
    Funder: Horizon 2020 Research and Innovation Framework Programme .
    Code: H2020-SC1-BHC-02-2019 / 847912-2.
    Duration: 01/01/2020 - 31/12/2024
  • Targeting immune checkpoints and metabolic reprogramming synergic vulnerabilities in metastatic colorectal cancer (IMMETCOL)

    Principal investigator: Joan Maurel.
    Funder: Instituto de Salud Carlos III (Sede).
    Duration: 01/01/2020 - 01/01/2022
  • Adoptive cell therapy using CD3+/PD1+ tumor infiltrating lymphocytes in patients with advanced breast cancer

    Principal investigator: Aleix Prat Aparicio.
    Funder: AECC, Fundación Científica Asociación Española Contra el Cáncer ; Hospital Clinic de Baarcelona (Participante); Clínica Universidad de Navarra (Participante); Vall d'Hebron Institut d'Oncologia (Participante); HOSPITAL UNIVERSITARIO 12 DE OCTUBRE (Partic.
    Code: GCAEC19010PRAT.
    Duration: 01/12/2019 - 30/11/2024
  • Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes

    Principal investigator: Aleix Prat Aparicio.
    Funder: Fundacion AECC .
    Duration: 15/09/2019 - 14/09/2022
  • AACR 2019 - Tailoring systemic treatment of Luminal B breast cancer

    Principal investigator: Patricia Galvan, Aleix Prat Aparicio.
    Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research .
    Code: BCRF_AACR_18_001.
    Duration: 01/07/2019 - 30/06/2021
  • Caracterización de los linfocitos T CD8+/PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched.

    Principal investigator: Aleix Prat Aparicio.
    Funder: Merck Farma y Química, S.L .
    Code: 19-IO-011.
    Duration: 01/07/2019 - 30/06/2021
  • Prospective exploratory study for determination of circulating tumor DNA (ctDNA) in blood samples from patients treated for breast cancer in follow-up and without evidence of relapse (B-CRONOS) KEYWORDS : Breast cancer, ctDNA, luminal, high risk

    Principal investigator: Aleix Prat Aparicio.
    Funder: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede); Fundación Quiron Salaud ; Fundación Quirón Salud .
    Code: TERAPIA_AMIGOS_18_01.
    Duration: 11/02/2019 - 10/02/2022
  • Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer. Breast Cancer Now (Breast Cancer Now)

    Duration: 01/01/2019 - 01/01/2022

Major founders

The research of this group can be carried out thanks to the funders.

Contributors

Donations that make possible the research of this group.